PL3427748T3 - Leczenie skojarzone niedokrwienia - Google Patents

Leczenie skojarzone niedokrwienia

Info

Publication number
PL3427748T3
PL3427748T3 PL18190827T PL18190827T PL3427748T3 PL 3427748 T3 PL3427748 T3 PL 3427748T3 PL 18190827 T PL18190827 T PL 18190827T PL 18190827 T PL18190827 T PL 18190827T PL 3427748 T3 PL3427748 T3 PL 3427748T3
Authority
PL
Poland
Prior art keywords
ischemia
combination therapy
therapy
combination
Prior art date
Application number
PL18190827T
Other languages
English (en)
Inventor
Michael Tymianski
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of PL3427748T3 publication Critical patent/PL3427748T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Dermatology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18190827T 2011-06-24 2012-06-23 Leczenie skojarzone niedokrwienia PL3427748T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161501117P 2011-06-24 2011-06-24
US201261617001P 2012-03-28 2012-03-28
EP12802409.8A EP2723363B1 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia
EP18190827.8A EP3427748B1 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia
PCT/IB2012/053178 WO2012176172A2 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia

Publications (1)

Publication Number Publication Date
PL3427748T3 true PL3427748T3 (pl) 2022-05-30

Family

ID=47423033

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18190827T PL3427748T3 (pl) 2011-06-24 2012-06-23 Leczenie skojarzone niedokrwienia
PL12802409T PL2723363T3 (pl) 2011-06-24 2012-06-23 Leczenie skojarzone niedokrwienia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12802409T PL2723363T3 (pl) 2011-06-24 2012-06-23 Leczenie skojarzone niedokrwienia

Country Status (19)

Country Link
US (3) US10064910B2 (pl)
EP (3) EP3427748B1 (pl)
JP (5) JP6401057B2 (pl)
KR (5) KR20220106862A (pl)
CN (1) CN103648518B (pl)
AU (1) AU2012274910B2 (pl)
CA (1) CA2839630A1 (pl)
CY (1) CY1121379T1 (pl)
DK (2) DK2723363T3 (pl)
ES (2) ES2690994T3 (pl)
HR (2) HRP20220519T1 (pl)
HU (2) HUE058238T2 (pl)
LT (1) LT2723363T (pl)
PL (2) PL3427748T3 (pl)
PT (2) PT2723363T (pl)
RS (1) RS57798B1 (pl)
SI (1) SI2723363T1 (pl)
SM (1) SMT201800592T1 (pl)
WO (1) WO2012176172A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2440230B1 (en) 2009-06-10 2020-11-11 NoNO Inc. Treatment regimes for treatment of neurological disease
PT2723363T (pt) 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika
WO2015023830A1 (en) * 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
EP3074030A4 (en) * 2013-11-26 2017-08-16 Trustees of Dartmouth College Method for mitigating or alleviating synaptic and cognitive deficits
FR3021319B1 (fr) * 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
CZ309217B6 (cs) * 2014-05-27 2022-06-01 Ústav Organické Chemie A Biochemie Av Čr, V.V.I. Lipidované peptidy jako neuroprotektiva
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN104497106B (zh) * 2014-12-05 2017-05-10 华中科技大学 一种小分子多肽、其应用及产品
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
WO2017185250A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
CN106265594B (zh) * 2016-09-21 2019-07-26 南京医科大学 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法
CN106749559B (zh) * 2016-11-23 2020-09-04 郑州大学 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法
JP7109958B2 (ja) * 2017-04-04 2022-08-01 キヤノンメディカルシステムズ株式会社 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法
CN110799522B (zh) * 2017-07-05 2023-08-29 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
EP3650460A4 (en) * 2017-07-05 2021-03-17 Biocells (Beijing) Biotech Co., Ltd. PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES
EA202090802A1 (ru) * 2017-09-30 2020-08-05 Биоселз (Бейдзин) Биотек Ко., Лтд. Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
US12122811B2 (en) 2018-04-06 2024-10-22 Northwestern University BDNF mimetic peptide amphiphiles
JP7158904B2 (ja) * 2018-06-14 2022-10-24 社会福祉法人 恩賜財団済生会熊本病院 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
CA3166998A1 (en) * 2020-01-09 2021-07-15 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
US20230285504A1 (en) * 2020-02-19 2023-09-14 Nono Inc. Inhibition of reperfusion injury with a psd-95 inhibitor
IL295727A (en) * 2020-02-19 2022-10-01 Nono Inc Combined treatment of stroke with a plasmin-degradable and reperfusion psd-95 inhibitor
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
WO2023192848A1 (en) * 2022-03-28 2023-10-05 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
AU2024208633A1 (en) 2023-01-09 2025-07-24 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Neuroprotective psd-95 polypeptide inhibitor and use thereof
CN117422722B (zh) * 2023-12-19 2024-03-29 北京智源人工智能研究院 基于adc图像的肿瘤预后特征评估的方法和装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742152B1 (fr) 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
JP2006524701A (ja) 2003-04-25 2006-11-02 ミトス・インコーポレーテッド 酸化防止剤による予防的前処置
BRPI0409865A (pt) * 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
MXPA05012515A (es) * 2003-05-19 2006-05-25 Kenneth S Warren Inst Inc Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada.
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
DK2043671T3 (da) 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
GB0707348D0 (en) 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8071555B2 (en) 2007-10-29 2011-12-06 Helix Biomedix Inc. Protective skin care peptides
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
MX2010008083A (es) 2008-01-25 2010-12-20 Univ Aarhus Inhibicion de exositios selectivos de actividad papp-a contra igfbp-4.
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CA2665302A1 (en) 2009-05-01 2010-11-01 Universite De Montreal Cd36 modulation and uses thereof
CA2765171C (en) 2009-06-10 2018-10-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP2440230B1 (en) 2009-06-10 2020-11-11 NoNO Inc. Treatment regimes for treatment of neurological disease
US20110144029A1 (en) 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
PT2723363T (pt) 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
WO2013088382A1 (en) 2011-12-13 2013-06-20 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
AU2012274910A1 (en) 2014-01-16
EP2723363A4 (en) 2014-12-10
KR102296106B1 (ko) 2021-08-30
JP2022188068A (ja) 2022-12-20
JP2014520142A (ja) 2014-08-21
JP7143374B2 (ja) 2022-09-28
ES2912042T3 (es) 2022-05-24
LT2723363T (lt) 2018-10-25
KR102140169B1 (ko) 2020-07-31
KR20140053971A (ko) 2014-05-08
JP6401057B2 (ja) 2018-10-03
RS57798B1 (sr) 2018-12-31
US20140248257A1 (en) 2014-09-04
HUE040564T2 (hu) 2019-03-28
JP2019038831A (ja) 2019-03-14
KR20200092437A (ko) 2020-08-03
SI2723363T1 (sl) 2018-12-31
US20210308209A1 (en) 2021-10-07
KR102022116B1 (ko) 2019-09-18
CA2839630A1 (en) 2012-12-27
HUE058238T2 (hu) 2022-07-28
JP2017193535A (ja) 2017-10-26
CN103648518B (zh) 2016-11-16
SMT201800592T1 (it) 2019-01-11
HRP20181526T1 (hr) 2018-12-14
WO2012176172A2 (en) 2012-12-27
EP4052721A1 (en) 2022-09-07
KR102425466B1 (ko) 2022-07-25
CN103648518A (zh) 2014-03-19
PT3427748T (pt) 2022-05-03
PL2723363T3 (pl) 2018-12-31
US10064910B2 (en) 2018-09-04
CY1121379T1 (el) 2020-05-29
JP2020189859A (ja) 2020-11-26
KR20220106862A (ko) 2022-07-29
WO2012176172A3 (en) 2013-03-28
ES2690994T3 (es) 2018-11-23
DK2723363T3 (en) 2018-10-15
US20190091283A1 (en) 2019-03-28
AU2012274910B2 (en) 2017-05-11
US11878044B2 (en) 2024-01-23
KR20190107195A (ko) 2019-09-18
PT2723363T (pt) 2018-11-08
EP2723363B1 (en) 2018-08-29
EP3427748B1 (en) 2022-03-02
HRP20220519T1 (hr) 2022-05-27
EP2723363A2 (en) 2014-04-30
DK3427748T3 (da) 2022-04-19
JP7085457B2 (ja) 2022-06-16
EP3427748A1 (en) 2019-01-16
US10967041B2 (en) 2021-04-06
KR20210109661A (ko) 2021-09-06

Similar Documents

Publication Publication Date Title
LT2723363T (lt) Išemijos politerapija
ZA201305897B (en) Combination therapy
TWI560388B (en) Dampferzeugerheizrohrreparaturmittel und reparaturverfahren
IL233154A0 (en) compounds
GB201106395D0 (en) Compounds
GB201109763D0 (en) Compounds
ZA201306857B (en) Mesogen-containing compounds
ZA201400120B (en) Combination therapy
GB201107197D0 (en) Compounds
GB201122139D0 (en) Compounds
EP2691581A4 (en) joint assembly
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
EP2701744A4 (en) COMBINATION THERAPY
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201118613D0 (en) Compounds
GB201114226D0 (en) Combination therapy
GB201106339D0 (en) Combination
GB201121105D0 (en) Combination
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201116059D0 (en) Project P
GB201110793D0 (en) Easy carry
GB201114533D0 (en) Concept 36A